Apalutamide
- Generic Name
- Apalutamide
- Brand Names
- Erleada
- Drug Type
- Small Molecule
- Chemical Formula
- C21H15F4N5O2S
- CAS Number
- 956104-40-8
- Unique Ingredient Identifier
- 4T36H88UA7
- Background
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Ne...
- Indication
Apalutamide is indicated for the treatment of patients with metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer.
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Non-Metastatic Castration-Resistant Prostate Cancer
- Associated Therapies
- Androgen Deprivation Therapy
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT03821792
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Apalutamide Administered Orally as Whole Tablets and as a Mixture in Applesauce in Healthy Participants
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT03802682
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT03777982
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center, Milford, Massachusetts, United States
🇺🇸Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital, South Weymouth, Massachusetts, United States
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 2517
- Registration Number
- NCT03767244
- Locations
- 🇺🇸
UC Davis Medical Center, Sacramento, California, United States
🇺🇸AdventHealth Medical Group Urology of Denver, Denver, Colorado, United States
🇺🇸Colorado Clinical Research, Lakewood, Colorado, United States
A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 19
- Registration Number
- NCT03523442
- Locations
- 🇨🇳
Beijing Cancer Hospital of Peking University, Beijing, China
🇨🇳Jiangsu Cancer Hospital, NanJing, China
🇨🇳Peking University Third Hospital, Beijing, China
An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer
- Conditions
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Registration Number
- NCT03523338
- Locations
- 🇧🇷
Ynova Pesquisa Clinica, Florianopolis, Brazil
🇧🇷Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, Brazil
🇧🇷Fundacao Antonio Prudente - A.C. Camargo Cancer Center, Sao Paulo, Brazil
Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-04-19
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 26
- Registration Number
- NCT03503344
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer
- Conditions
- Interventions
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 102
- Registration Number
- NCT03436654
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Northwestern University, Evanston, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT03412396
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.